Profound Medical Corp.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M | $6.7M | $6.9M | $7.3M | $4.2M |
| Cost of Revenue | $4.7M | $3.6M | $2.9M | $3.7M | $3.9M | $3.8M | $1.8M |
| Gross Profit | $11.4M | $7.0M | $4.3M | $3.0M | $3.0M | $3.5M | $2.4M |
| Gross Margin | 70.8% | 65.9% | 59.9% | 45.2% | 43.0% | 47.6% | 57.3% |
| Operating Expenses | |||||||
| Research & Development | $20.6M | $17.0M | $14.4M | — | — | — | — |
| SG&A Expense | $32.1M | $23.1M | $18.5M | — | — | — | — |
| Operating Income | $-41.3M | $-33.1M | $-28.7M | $-32.1M | $-30.3M | $-18.9M | $-14.9M |
| Operating Margin | -256.3% | -309.6% | -398.0% | -480.9% | -440.7% | -258.3% | -357.1% |
| Interest Expense | $394.0K | $600.0K | $146.0K | $290.0K | $448.0K | — | — |
| Pretax Income | $-42.3M | $-27.8M | $-28.5M | $-28.4M | $-30.6M | $-21.6M | $-15.1M |
| Income Tax Expense | $252.0K | $-2.0K | $-128.0K | $287.0K | $105.0K | $45.0K | $147.0K |
| Net Income | $-42.6M | $-27.8M | $-28.3M | $-28.7M | $-30.7M | $-21.6M | $-15.2M |
| Net Margin | -264.4% | -260.4% | -393.4% | -429.1% | -446.7% | -296.0% | -364.7% |
| EPS (Basic) | $1.41 | $1.12 | $1.34 | $1.38 | $1.50 | $1.25 | — |
| EPS (Diluted) | $1.41 | $1.12 | $1.34 | $1.38 | $1.50 | $1.25 | — |
| Shares Outstanding (Basic) | 30.2M | 24.8M | 21.2M | 20.9M | 20.8M | 20.2M | 11.9M |
| Shares Outstanding (Diluted) | 30.2M | 24.8M | 21.2M | 20.9M | 20.8M | 20.2M | 11.9M |
| Dividends Per Share | — | — | — | — | — | — | — |